A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study

Sara Gagno, Mario Rosario D'Andrea, Mauro Mansutti, Chiara Zanusso, Fabio Puglisi, Eva Dreussi, Marcella Montico, Paola Biason, Erika Cecchin, Donatella Iacono, Stefania Russo, Marika Cinausero, Silvana Saracchini, Giampietro Gasparini, Donata Sartori, Mario Bari, Elena Collovà, Rosa Meo, Ghassan Merkabaoui, Ilaria SpagnolettiArianna Pellegrino, Lorenzo Gianni, Paolo Sandri, Elisabetta Cretella, Emanuela Vattemi, Andrea Rocca, Patrizia Serra, Maria Agnese Fabbri, Giovanni Benedetti, Laura Foghini, Michele Medici, Umberto Basso, Vito Amoroso, Ferdinando Riccardi, Anna Maria Baldelli, Mario Clerico, Salvatore Bonura, Chiara Saggia, Federico Innocenti, Giuseppe Toffoli

Research output: Contribution to journalArticle

Abstract

Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.

Original languageEnglish
JournalClinical Breast Cancer
DOIs
Publication statusE-pub ahead of print - Jan 1 2018

Fingerprint

exemestane
Prospective Studies
Breast Neoplasms
Biomarkers
Population
Therapeutics

Keywords

  • Advanced breast cancer
  • Aromatase inhibitor
  • Hormone therapy
  • Polymorphisms
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane : Results From a Prospective Study. / Gagno, Sara; D'Andrea, Mario Rosario; Mansutti, Mauro; Zanusso, Chiara; Puglisi, Fabio; Dreussi, Eva; Montico, Marcella; Biason, Paola; Cecchin, Erika; Iacono, Donatella; Russo, Stefania; Cinausero, Marika; Saracchini, Silvana; Gasparini, Giampietro; Sartori, Donata; Bari, Mario; Collovà, Elena; Meo, Rosa; Merkabaoui, Ghassan; Spagnoletti, Ilaria; Pellegrino, Arianna; Gianni, Lorenzo; Sandri, Paolo; Cretella, Elisabetta; Vattemi, Emanuela; Rocca, Andrea; Serra, Patrizia; Fabbri, Maria Agnese; Benedetti, Giovanni; Foghini, Laura; Medici, Michele; Basso, Umberto; Amoroso, Vito; Riccardi, Ferdinando; Baldelli, Anna Maria; Clerico, Mario; Bonura, Salvatore; Saggia, Chiara; Innocenti, Federico; Toffoli, Giuseppe.

In: Clinical Breast Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Gagno, S, D'Andrea, MR, Mansutti, M, Zanusso, C, Puglisi, F, Dreussi, E, Montico, M, Biason, P, Cecchin, E, Iacono, D, Russo, S, Cinausero, M, Saracchini, S, Gasparini, G, Sartori, D, Bari, M, Collovà, E, Meo, R, Merkabaoui, G, Spagnoletti, I, Pellegrino, A, Gianni, L, Sandri, P, Cretella, E, Vattemi, E, Rocca, A, Serra, P, Fabbri, MA, Benedetti, G, Foghini, L, Medici, M, Basso, U, Amoroso, V, Riccardi, F, Baldelli, AM, Clerico, M, Bonura, S, Saggia, C, Innocenti, F & Toffoli, G 2018, 'A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study', Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2018.11.009
Gagno, Sara ; D'Andrea, Mario Rosario ; Mansutti, Mauro ; Zanusso, Chiara ; Puglisi, Fabio ; Dreussi, Eva ; Montico, Marcella ; Biason, Paola ; Cecchin, Erika ; Iacono, Donatella ; Russo, Stefania ; Cinausero, Marika ; Saracchini, Silvana ; Gasparini, Giampietro ; Sartori, Donata ; Bari, Mario ; Collovà, Elena ; Meo, Rosa ; Merkabaoui, Ghassan ; Spagnoletti, Ilaria ; Pellegrino, Arianna ; Gianni, Lorenzo ; Sandri, Paolo ; Cretella, Elisabetta ; Vattemi, Emanuela ; Rocca, Andrea ; Serra, Patrizia ; Fabbri, Maria Agnese ; Benedetti, Giovanni ; Foghini, Laura ; Medici, Michele ; Basso, Umberto ; Amoroso, Vito ; Riccardi, Ferdinando ; Baldelli, Anna Maria ; Clerico, Mario ; Bonura, Salvatore ; Saggia, Chiara ; Innocenti, Federico ; Toffoli, Giuseppe. / A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane : Results From a Prospective Study. In: Clinical Breast Cancer. 2018.
@article{b994b1018d664b978f543ca1889ef8a5,
title = "A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective Study",
abstract = "Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.",
keywords = "Advanced breast cancer, Aromatase inhibitor, Hormone therapy, Polymorphisms, Survival",
author = "Sara Gagno and D'Andrea, {Mario Rosario} and Mauro Mansutti and Chiara Zanusso and Fabio Puglisi and Eva Dreussi and Marcella Montico and Paola Biason and Erika Cecchin and Donatella Iacono and Stefania Russo and Marika Cinausero and Silvana Saracchini and Giampietro Gasparini and Donata Sartori and Mario Bari and Elena Collov{\`a} and Rosa Meo and Ghassan Merkabaoui and Ilaria Spagnoletti and Arianna Pellegrino and Lorenzo Gianni and Paolo Sandri and Elisabetta Cretella and Emanuela Vattemi and Andrea Rocca and Patrizia Serra and Fabbri, {Maria Agnese} and Giovanni Benedetti and Laura Foghini and Michele Medici and Umberto Basso and Vito Amoroso and Ferdinando Riccardi and Baldelli, {Anna Maria} and Mario Clerico and Salvatore Bonura and Chiara Saggia and Federico Innocenti and Giuseppe Toffoli",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.clbc.2018.11.009",
language = "English",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",

}

TY - JOUR

T1 - A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane

T2 - Results From a Prospective Study

AU - Gagno, Sara

AU - D'Andrea, Mario Rosario

AU - Mansutti, Mauro

AU - Zanusso, Chiara

AU - Puglisi, Fabio

AU - Dreussi, Eva

AU - Montico, Marcella

AU - Biason, Paola

AU - Cecchin, Erika

AU - Iacono, Donatella

AU - Russo, Stefania

AU - Cinausero, Marika

AU - Saracchini, Silvana

AU - Gasparini, Giampietro

AU - Sartori, Donata

AU - Bari, Mario

AU - Collovà, Elena

AU - Meo, Rosa

AU - Merkabaoui, Ghassan

AU - Spagnoletti, Ilaria

AU - Pellegrino, Arianna

AU - Gianni, Lorenzo

AU - Sandri, Paolo

AU - Cretella, Elisabetta

AU - Vattemi, Emanuela

AU - Rocca, Andrea

AU - Serra, Patrizia

AU - Fabbri, Maria Agnese

AU - Benedetti, Giovanni

AU - Foghini, Laura

AU - Medici, Michele

AU - Basso, Umberto

AU - Amoroso, Vito

AU - Riccardi, Ferdinando

AU - Baldelli, Anna Maria

AU - Clerico, Mario

AU - Bonura, Salvatore

AU - Saggia, Chiara

AU - Innocenti, Federico

AU - Toffoli, Giuseppe

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.

AB - Currently there are no reliable biomarkers to predict outcome of exemestane treatment. We designed a prospective study to investigate whether constitutive genetic background might affect response to therapy. In a population of 302 advanced breast cancer patients treated with exemestane we showed that a 5–polymorphism-based genetic score could be used to identify patients with different risks of progression and death.

KW - Advanced breast cancer

KW - Aromatase inhibitor

KW - Hormone therapy

KW - Polymorphisms

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85058825217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058825217&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2018.11.009

DO - 10.1016/j.clbc.2018.11.009

M3 - Article

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

ER -